Selected research
Industry Research
Polycythemia Vera Drug Industry Research Report 2026
Market perspective
The global Polycythemia Vera Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Polycythemia Vera Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Polycythemia Vera Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Polycythemia Vera Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Polycythemia Vera Drug include ANP Technologies, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Galena Biopharma, Inc., Gilead Sciences, Inc., Italfarmaco S.p.A., Karus Therapeutics Limited, miRagen Therapeutics, Inc. and Nerviano Medical Sciences S.r.l., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Polycythemia Vera Drug market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Polycythemia Vera Drug Market by Company
ANP Technologies, Inc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Galena Biopharma, Inc.
Gilead Sciences, Inc.
Italfarmaco S.p.A.
Karus Therapeutics Limited
miRagen Therapeutics, Inc.
Nerviano Medical Sciences S.r.l.
PharmaEssentia Corporation
Novartis AG
Teva Pharmaceutical Industries Ltd.
Polycythemia Vera Drug Segment by Type
Idelalisib
Givinostat
Dasatinib
M-009
Others
Polycythemia Vera Drug Segment by Application
Clinic
Hospital
Others
Polycythemia Vera Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Polycythemia Vera Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Polycythemia Vera Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Polycythemia Vera Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Polycythemia Vera Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Polycythemia Vera Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Polycythemia Vera Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Idelalisib
- Givinostat
- Dasatinib
- M-009
- Others
Applications
- Clinic
- Hospital
- Others
Companies covered
- ANP Technologies, Inc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Galena Biopharma, Inc.
- Gilead Sciences, Inc.
- Italfarmaco S.p.A.
- Karus Therapeutics Limited
- miRagen Therapeutics, Inc.
- Nerviano Medical Sciences S.r.l.
- PharmaEssentia Corporation
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Polycythemia Vera Drug Market Size (2021-2032)
- 2.2.2 Global Polycythemia Vera Drug Sales (2021-2032)
- 2.2.3 Global Polycythemia Vera Drug Market Average Price (2021-2032)
- 2.3 Polycythemia Vera Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Idelalisib
- 2.3.3 Givinostat
- 2.3.4 Dasatinib
- 2.3.5 M-009
- 2.3.6 Others
- 2.4 Polycythemia Vera Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Clinic
- 2.4.3 Hospital
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Polycythemia Vera Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Polycythemia Vera Drug Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Polycythemia Vera Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Polycythemia Vera Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Polycythemia Vera Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Polycythemia Vera Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Polycythemia Vera Drug, Product Type & Application
- 3.8 Global Manufacturers of Polycythemia Vera Drug, Established Date
- 3.9 Global Polycythemia Vera Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 ANP Technologies, Inc.
- 4.1.1 ANP Technologies, Inc. Company Information
- 4.1.2 ANP Technologies, Inc. Business Overview
- 4.1.3 ANP Technologies, Inc. Polycythemia Vera Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 ANP Technologies, Inc. Polycythemia Vera Drug Product Portfolio
- 4.1.5 ANP Technologies, Inc. Recent Developments
- 4.2 Bristol-Myers Squibb Company
- 4.2.1 Bristol-Myers Squibb Company Company Information
- 4.2.2 Bristol-Myers Squibb Company Business Overview
- 4.2.3 Bristol-Myers Squibb Company Polycythemia Vera Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Bristol-Myers Squibb Company Polycythemia Vera Drug Product Portfolio
- 4.2.5 Bristol-Myers Squibb Company Recent Developments
- 4.3 F. Hoffmann-La Roche Ltd.
- 4.3.1 F. Hoffmann-La Roche Ltd. Company Information
- 4.3.2 F. Hoffmann-La Roche Ltd. Business Overview
- 4.3.3 F. Hoffmann-La Roche Ltd. Polycythemia Vera Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 F. Hoffmann-La Roche Ltd. Polycythemia Vera Drug Product Portfolio
- 4.3.5 F. Hoffmann-La Roche Ltd. Recent Developments
- 4.4 Galena Biopharma, Inc.
- 4.4.1 Galena Biopharma, Inc. Company Information
- 4.4.2 Galena Biopharma, Inc. Business Overview
- 4.4.3 Galena Biopharma, Inc. Polycythemia Vera Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Galena Biopharma, Inc. Polycythemia Vera Drug Product Portfolio
- 4.4.5 Galena Biopharma, Inc. Recent Developments
- 4.5 Gilead Sciences, Inc.
- 4.5.1 Gilead Sciences, Inc. Company Information
- 4.5.2 Gilead Sciences, Inc. Business Overview
- 4.5.3 Gilead Sciences, Inc. Polycythemia Vera Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Gilead Sciences, Inc. Polycythemia Vera Drug Product Portfolio
- 4.5.5 Gilead Sciences, Inc. Recent Developments
- 4.6 Italfarmaco S.p.A.
- 4.6.1 Italfarmaco S.p.A. Company Information
- 4.6.2 Italfarmaco S.p.A. Business Overview
- 4.6.3 Italfarmaco S.p.A. Polycythemia Vera Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Italfarmaco S.p.A. Polycythemia Vera Drug Product Portfolio
- 4.6.5 Italfarmaco S.p.A. Recent Developments
- 4.7 Karus Therapeutics Limited
- 4.7.1 Karus Therapeutics Limited Company Information
- 4.7.2 Karus Therapeutics Limited Business Overview
- 4.7.3 Karus Therapeutics Limited Polycythemia Vera Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Karus Therapeutics Limited Polycythemia Vera Drug Product Portfolio
- 4.7.5 Karus Therapeutics Limited Recent Developments
- 4.8 miRagen Therapeutics, Inc.
- 4.8.1 miRagen Therapeutics, Inc. Company Information
- 4.8.2 miRagen Therapeutics, Inc. Business Overview
- 4.8.3 miRagen Therapeutics, Inc. Polycythemia Vera Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 miRagen Therapeutics, Inc. Polycythemia Vera Drug Product Portfolio
- 4.8.5 miRagen Therapeutics, Inc. Recent Developments
- 4.9 Nerviano Medical Sciences S.r.l.
- 4.9.1 Nerviano Medical Sciences S.r.l. Company Information
- 4.9.2 Nerviano Medical Sciences S.r.l. Business Overview
- 4.9.3 Nerviano Medical Sciences S.r.l. Polycythemia Vera Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Nerviano Medical Sciences S.r.l. Polycythemia Vera Drug Product Portfolio
- 4.9.5 Nerviano Medical Sciences S.r.l. Recent Developments
- 4.10 PharmaEssentia Corporation
- 4.10.1 PharmaEssentia Corporation Company Information
- 4.10.2 PharmaEssentia Corporation Business Overview
- 4.10.3 PharmaEssentia Corporation Polycythemia Vera Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 PharmaEssentia Corporation Polycythemia Vera Drug Product Portfolio
- 4.10.5 PharmaEssentia Corporation Recent Developments
- 4.11 Novartis AG
- 4.11.1 Novartis AG Company Information
- 4.11.2 Novartis AG Business Overview
- 4.11.3 Novartis AG Polycythemia Vera Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Novartis AG Polycythemia Vera Drug Product Portfolio
- 4.11.5 Novartis AG Recent Developments
- 4.12 Teva Pharmaceutical Industries Ltd.
- 4.12.1 Teva Pharmaceutical Industries Ltd. Company Information
- 4.12.2 Teva Pharmaceutical Industries Ltd. Business Overview
- 4.12.3 Teva Pharmaceutical Industries Ltd. Polycythemia Vera Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Teva Pharmaceutical Industries Ltd. Polycythemia Vera Drug Product Portfolio
- 4.12.5 Teva Pharmaceutical Industries Ltd. Recent Developments
5 Global Polycythemia Vera Drug Market Scenario by Region
- 5.1 Global Polycythemia Vera Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Polycythemia Vera Drug Sales by Region: 2021-2032
- 5.2.1 Global Polycythemia Vera Drug Sales by Region: 2021-2026
- 5.2.2 Global Polycythemia Vera Drug Sales by Region: 2027-2032
- 5.3 Global Polycythemia Vera Drug Revenue by Region: 2021-2032
- 5.3.1 Global Polycythemia Vera Drug Revenue by Region: 2021-2026
- 5.3.2 Global Polycythemia Vera Drug Revenue by Region: 2027-2032
- 5.4 North America Polycythemia Vera Drug Market Facts & Figures by Country
- 5.4.1 North America Polycythemia Vera Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Polycythemia Vera Drug Sales by Country (2021-2032)
- 5.4.3 North America Polycythemia Vera Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Polycythemia Vera Drug Market Facts & Figures by Country
- 5.5.1 Europe Polycythemia Vera Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Polycythemia Vera Drug Sales by Country (2021-2032)
- 5.5.3 Europe Polycythemia Vera Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Polycythemia Vera Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Polycythemia Vera Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Polycythemia Vera Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Polycythemia Vera Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Polycythemia Vera Drug Market Facts & Figures by Country
- 5.7.1 South America Polycythemia Vera Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Polycythemia Vera Drug Sales by Country (2021-2032)
- 5.7.3 South America Polycythemia Vera Drug Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Polycythemia Vera Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Polycythemia Vera Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Polycythemia Vera Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Polycythemia Vera Drug Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Polycythemia Vera Drug Sales by Type (2021-2032)
- 6.1.1 Global Polycythemia Vera Drug Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Polycythemia Vera Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Polycythemia Vera Drug Revenue by Type (2021-2032)
- 6.2.1 Global Polycythemia Vera Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Polycythemia Vera Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Polycythemia Vera Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Polycythemia Vera Drug Sales by Application (2021-2032)
- 7.1.1 Global Polycythemia Vera Drug Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Polycythemia Vera Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Polycythemia Vera Drug Revenue by Application (2021-2032)
- 7.2.1 Global Polycythemia Vera Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Polycythemia Vera Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Polycythemia Vera Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Polycythemia Vera Drug Value Chain Analysis
- 8.1.1 Polycythemia Vera Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Polycythemia Vera Drug Production Mode & Process
- 8.2 Polycythemia Vera Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Polycythemia Vera Drug Distributors
- 8.2.3 Polycythemia Vera Drug Customers
9 Global Polycythemia Vera Drug Analyzing Market Dynamics
- 9.1 Polycythemia Vera Drug Industry Trends
- 9.2 Polycythemia Vera Drug Industry Drivers
- 9.3 Polycythemia Vera Drug Industry Opportunities and Challenges
- 9.4 Polycythemia Vera Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst